



ECNP
Research & Scholarship
Foundation
Annual Report 2025

ECNP Research and Scholarship Foundation

Annual Report 2025

1. About ECNP R&S	3
Objectives	3
Board	3
2. Activities 2025	4
Scientific and educational meetings	4
Awards	5
Other major initiatives	5
3. Financial Overview	6
Financial statements	7
4. Future Outlook	9



The Stichting ECNP Research and Scholarship Foundation is a public-interest-serving entity (*algemeen nut beogende instelling* – ANBI) under Dutch tax law.

1. About ECNP R&S

The Stichting ECNP Research and Scholarship Foundation (ECNP R&S) is an independent foundation that supports the ECNP consortium of entities.

Address:	Daltonlaan 400, 3584 BK Utrecht, The Netherlands
E-mail:	secretariat@ecnp.eu
Website:	https://www.ecnp.eu
RSIN:	807967087
Dutch Chamber of Commerce number:	41215196
Dutch TAX number:	NL807967087B01
ANBI:	The Stichting ECNP Research and Scholarship Foundation is a public-interest-serving entity (<i>algemeen nut beogende instelling</i> – ANBI) under Dutch tax law.

Objectives

ECNP R&S exists to promote high-quality experimental and clinical research and education in applied and translational neuroscience, with a view to stimulating the development of better treatments for those suffering disorders of the brain.

The foundation also provides a framework for the organisation of the annual congresses of ECNP. It is a non-profit making body.

Board

Up to 13 October 2025

Martien Kas
Chairman
The Netherlands

Brenda Penninx
Treasurer
The Netherlands

Suzanne Dickson
Secretary
Sweden

From 13 October 2025

Andreas Reif
President
Germany

John Cryan
Treasurer
Ireland

Marion Leboyer
Secretary
France

The members of the board receive no remuneration for their role.

Alexander Schubert
Executive Director
The Netherlands

2. Activities 2025

To execute its mission to support European applied and translational neuroscience, ECNP R&S performs a number of activities annually, focusing especially on stimulating research, sponsoring education and raising awareness.

In 2025 the following programmes were delivered:

Scientific and educational meetings

- **ECNP Workshop for Early Career Scientists in Europe**

20-23 March 2025 – Nice, France

The Workshop offers 100 European early career scientists three days of intense interaction with research leaders discussing the latest advances and perspectives in translational neuroscience.

- **ECNP New Frontiers Meeting: Targeting neural circuits in psychiatry**

23-24 March 2025 – Nice, France

A unique platform for focused, high-level exchange between scientists, industry leaders and regulators at the intersection of research science and new treatment development. The 2024 meeting explored how circuit-based understandings of psychiatric illness are challenging traditional diagnostic classification and therapeutic specificity.

- **ECNP Workshop on Clinical Research Methods**

3-5 December 2025 – Barcelona, Spain

The Workshop offers 50 European early career scientists three days of training on research methodology and critical approaches to the scientific literature for early career scientists.

Awards

- **ECNP Downloads Prize**

Awarded to the most-downloaded research paper in the ECNP journal, *Neuroscience Applied* (NSA) in the preceding two years, the award recognises and encourages impactful original research.

Winner 2025: Karlijn Kooij, et al., 'GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling,' *Neuroscience Applied* 3 (2024) 103925.

- **ECNP Negative Results Prize**

Awarded to papers that have made exceptional contributions to CNS treatment science by publishing clinical research with negative findings.

The Best Negative Data Prize in Preclinical Neuroscience is planned for 2026, the next Best Negative Data Prize in Clinical Neuroscience for 2027.

Other major initiatives

- **Neuroscience-based Nomenclature (NbN)**

This international collaborative venture, led by ECNP, is working to develop a new nomenclature for psychotropic medications grounded in the latest advances in brain science. Unique in its aims and unprecedented in its scope, in 2025 the initiative's NbN app and NbN-ca app for child and adolescent treatments reached over 180,000 downloads worldwide, with translations in French, Spanish and Chinese, and Portuguese and patient-and-family versions in preparation.

- ***Neuroscience Applied***

Owned by ECNP R&S, this fully open-access scientific journal targets the intersection between neuroscience, applications and new treatment horizons, and features original basic, clinical and integrative research with translational relevance for mental health. Focusing especially on neuroscientific approaches to brain disorders, it encompasses mechanisms of disorders, biological, psychological and social treatments, prevention and policies.

- **ECNP Knowledge Hub**

The Knowledge Hub brings together all of ECNP's expanding repertoire of online content to provide a central repository of information, knowledge tools, and learning resources for researchers and clinicians across the spectrum of applied neuroscience. Already featuring educational courses, webinars and podcasts, the Knowledge Hub will be

progressively expanded to cover the breadth of information, learning and research needs and use the knowledge and skills of the ECNP community to advance the field. Since its launch in October 2024, it has hosted 12 courses, 46 webinars, 24 podcasts, and engaged over 4,600 active monthly users from 88 countries.

- **ECNP Roadmap Initiative**

The ECNP Roadmap Initiative was launched to co-ordinate and accelerate efforts to build a new biology-based diagnostic framework for mental disorders that will advance precision diagnostics and facilitate the development of innovative, mechanism-based treatment strategies beyond the current diagnostic boundaries. The initiative seeks to achieve global alignment with all stakeholders on the way forward to better define and measure neuropsychiatric conditions, harmonise methodologies and data sets across the community, and mobilise resources to implement and validate the framework. Launched at the 2024 ECNP New Frontiers Meeting, the follow-up ECNP Roadmap Meeting on Precision Psychiatry, 'Making precision psychiatry a reality', was held on 20-21 January 2025 in Frankfurt, Germany.

- **ECNP Early Career Academy**

The ECNP Early Career Academy (ECA) offers a range of benefits aimed at fostering connectivity between outstanding early career scientists, facilitating their sustained, career-long engagement in ECNP, and providing opportunities to amplify their contributions to applied neuroscience.

3. Financial Overview

ECNP R&S is funded from donations, in particular from the ECNP Congress Foundations, subsidies and grants, and income from its investment portfolio.

Its policy is at all times to handle its disposable assets in a responsible and sustainable manner, according to strict principles:

- Proactive tax and regulatory compliance
- Strict observance of the requirements of ANBI ('algemeen nut beogende instelling' = public-interest-service entity) status
- Capital preservation
- Budgetary discipline
- Ongoing diversification of the revenue base

To give substance to this, ECNP R&S invests in securities through an established asset manager using a defensive mandate. The goal is to preserve wealth, to ensure it can continue to deliver its activities and perform its public-good function, not to maximise return.

Financial statements

Balance sheet as at 31 December 2025

(after appropriation of profit/losses)

	31 December 2025		31 December 2024	
	€	€	€	€
ASSETS				
<u>FIXED ASSETS</u>				
<u>Financial fixed assets</u>				
Securities		11,018,368		11,018,368
<u>CURRENT ASSETS</u>				
<u>Receivables, prepayments and accrued income</u>				
Debtors	83,674		345,938	
Amounts owed by congress foundations	304,436		254,136	
Taxes	0		10,106	
Other receivables, deferred assets	153,874		142,208	
		541,984		752,388
<u>Bank deposits</u>		2,304,052		1,819,159
		<u>13,864,404</u>		<u>13,589,915</u>

	31 December 2025		31 December 2024	
	€	€	€	€
EQUITY AND LIABILITIES				
<u>EQUITY AND FUNDS</u>				
Other reserves		13,530,320		13,191,695
<u>CURRENT LIABILITIES</u>				
Creditors	108,037		34,399	
Taxes	5,893		0	
Other liabilities and accruals and deferred income	220,154		363,821	
		334,084		398,220
		<u>13,864,404</u>		<u>13,589,915</u>

Statement of income and expenditure 2025

	2025	2024
	€	€
Income		
Proceeds congress foundations	811,027	922,774
Journal Neuroscience Applied	25,282	20,703
Neuroscience-based Nomenclature	0	16,689
Income meetings & KH	438,814	86,425
Other income	26,692	69,998
Interest and similar income	31,693	51,387
<u>SUM OF INCOME</u>	<u>1,333,508</u>	<u>1,167,976</u>
Expenses		
Administration	395,728	365,396
Meetings	405,823	261,887
Journal Neuroscience Applied	64,244	53,590
Other activities	69,350	28,050
Other expenses	55,915	1,061,368
Bank charges	3,823	2,325
<u>SUM OF EXPENSES</u>	<u>994,883</u>	<u>1,772,616</u>
<u>RESULT</u>	<u>338,625</u>	<u>(604,640)</u>
Appropriation of the results		
Other reserves	<u>338,625</u>	<u>(604,640)</u>

4. Future Outlook

As the ECNP entities continue to develop and refine their purpose and strategy to determine where the most impactful contributions can be made and how relevance and long-term (economic) viability can be assured. Questions under review include:

- How the landscape of European brain science is changing and how ECNP's programmes and activities should adapt to these changes.
- How technology is reshaping the ways in which science is generated, disseminated and consumed, and how ECNP should respond.
- How the organisation's activities can meet the scale of the need they are designed to serve and achieve an impact commensurate with the organisation's mission.
- How the organisation can fulfil its social obligation to reduce its carbon footprint and contribute to environmental preservation.

The result of this process is an ongoing recalibration of the entities' portfolios both to optimise the quality and reach of their current activities and to increase their impact on the issues that shape the future of the field.

Promoting and disseminating science

The ECNP Networks programme, already one of the most productive collaborative platforms of its type in European applied neuroscience, will be expanded to include up to 30 thematic Networks, with ongoing refinement of the portfolio to ensure maximum topical coverage and research effectiveness.

The ECNP Roadmap for Precision Psychiatry will be broadened from its annual meeting to include ECNP-led research projects to advance precision psychiatry models and accelerate biomarker research.

Fostering talent

ECNP and its allied entities will continue to develop their educational offerings, leveraging in particular online delivery to reach the largest numbers of users with the highest-quality and most impactful content at the lowest cost and smallest environmental footprint.

A professional career development trajectory from Early Career Scientist to Fellow Member will be built to ensure that members of the ECNP community at all stages of their career are able to engage and benefit.

The ECNP Early Career Academy of exceptional early career scientists in Europe will be expanded with an additional 20 members, with a view bringing its total membership up to 100.

Public outreach

ECNP will address the pressing issue of European medicines innovation and the availability of the latest psychiatric treatments for European patients with an awareness-raising campaign to advocate for more patient-oriented policies and parity between mental illness and other disease areas.

